Jan 16, 2024, 05:48
Stephen V Liu: Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines
Stephen V Liu, Director of Thoracic Oncology and Developmental Therapeutics at Lombardi Comprehensive Cancer Center, posted on X/Twitter:
“Many updates in the 1.2024 National Comprehensive Cancer Network (NCCN) NSCLC guidelines including:
– amivantamab + carbo/pem preferred 1L for EGFR exon 20 (PAPILLON)
– amivantamab + carbo/pem for EGFR post osimertinib (MARIPOSA2)
– repotrectinib for 1L ROS1 (TRIDENT)
– atezolizumab monotherapy for PS3 (IPSOS).”
Source: Stephen V Liu/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 09:22
Dec 21, 2024, 09:06
Dec 21, 2024, 09:00
Dec 21, 2024, 08:51
Dec 21, 2024, 08:48
Dec 21, 2024, 08:42
Dec 21, 2024, 08:37
Dec 21, 2024, 08:29
Dec 21, 2024, 08:12